HomeCompareINRLF vs ARCC

INRLF vs ARCC: Dividend Comparison 2026

INRLF yields 63.90% · ARCC yields 10.65%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 INRLF wins by $762.8K in total portfolio value
10 years
INRLF
INRLF
● Live price
63.90%
Share price
$3.13
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$787.3K
Annual income
$193,029.75
Full INRLF calculator →
ARCC
Ares Capital Corporation
● Live price
10.65%
Share price
$18.02
Annual div
$1.92
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$24.5K
Annual income
$1.14
Full ARCC calculator →

Portfolio growth — INRLF vs ARCC

📍 INRLF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodINRLFARCC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, INRLF + ARCC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
INRLF pays
ARCC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

INRLF
Annual income on $10K today (after 15% tax)
$5,431.31/yr
After 10yr DRIP, annual income (after tax)
$164,075.29/yr
ARCC
Annual income on $10K today (after 15% tax)
$905.66/yr
After 10yr DRIP, annual income (after tax)
$0.97/yr
At 15% tax rate, INRLF beats the other by $164,074.32/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of INRLF + ARCC for your $10,000?

INRLF: 50%ARCC: 50%
100% ARCC50/50100% INRLF
Portfolio after 10yr
$405.9K
Annual income
$96,515.45/yr
Blended yield
23.78%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ARCC right now

INRLF
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
-1.2
Piotroski
3/9
ARCC
Analyst Ratings
24
Buy
7
Hold
Consensus: Buy
Price Target
$21.88
+21.4% upside vs current
Range: $21.00 — $23.00
Altman Z
0.8
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

INRLF buys
0
ARCC buys
0
No recent congressional trades found for INRLF or ARCC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricINRLFARCC
Forward yield63.90%10.65%
Annual dividend / share$2.00$1.92
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%-50%
Portfolio after 10y$787.3K$24.5K
Annual income after 10y$193,029.75$1.14
Total dividends collected$660.4K$1.1K
Payment frequencyquarterlyquarterly
SectorStockBDC
Analyst consensusBuyBuy

Year-by-year: INRLF vs ARCC ($10,000, DRIP)

YearINRLF PortfolioINRLF Income/yrARCC PortfolioARCC Income/yrGap
1← crossover$17,090$6,389.78$11,373$532.74+$5.7KINRLF
2$28,492$10,205.59$12,608$279.46+$15.9KINRLF
3$46,387$15,901.41$13,809$142.90+$32.6KINRLF
4$73,830$24,195.53$15,042$72.20+$58.8KINRLF
5$114,988$35,990.20$16,341$36.27+$98.6KINRLF
6$175,424$52,386.69$17,732$18.18+$157.7KINRLF
7$262,396$74,691.78$19,231$9.10+$243.2KINRLF
8$385,177$104,413.37$20,851$4.55+$364.3KINRLF
9$555,383$143,243.74$22,605$2.28+$532.8KINRLF
10$787,290$193,029.75$24,504$1.14+$762.8KINRLF

INRLF vs ARCC: Complete Analysis 2026

INRLFStock

Valneva SE, a specialty vaccine company, focuses on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing Enterotoxigenic Escherichia coli bacterium; and VLA2001, a vaccine candidate against SARS-CoV-2. The company also develops VLA15, a vaccine candidate that has completed Phase II clinical trial against Borrelia; and VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, other European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is headquartered in Saint-Herblain, France.

Full INRLF Calculator →

ARCCBDC

Ares Capital Corporation is a business development company specializing in acquisition, recapitalization, mezzanine debt, restructurings, rescue financing, and leveraged buyout transactions of middle market companies. It also makes growth capital and general refinancing. It prefers to make investments in companies engaged in the basic and growth manufacturing, business services, consumer products, health care products and services, and information technology service sectors. The fund will also consider investments in industries such as restaurants, retail, oil and gas, and technology sectors. It focuses on investments in Northeast, Mid-Atlantic, Southeast and Southwest regions from its New York office, the Midwest region, from the Chicago office, and the Western region from the Los Angeles office. The fund typically invests between $20 million and $200 million and a maximum of $400 million in companies with an EBITDA between $10 million and $250 million. It makes debt investments between $10 million and $100 million The fund invests through revolvers, first lien loans, warrants, unitranche structures, second lien loans, mezzanine debt, private high yield, junior capital, subordinated debt, and non-control preferred and common equity. The fund also selectively considers third-party-led senior and subordinated debt financings and opportunistically considers the purchase of stressed and discounted debt positions. The fund prefers to be an agent and/or lead the transactions in which it invests. The fund also seeks board representation in its portfolio companies.

Full ARCC Calculator →
📬

Get this INRLF vs ARCC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

INRLF vs SCHDINRLF vs JEPIINRLF vs OINRLF vs KOINRLF vs MAININRLF vs HTGCINRLF vs GBDCINRLF vs ORCC

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.